Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease

被引：0
|
作者：
Mateos, Maria-Victoria [1 ]
Usmani, Saad Z. [2 ]
Quach, Hang [3 ]
Dimopoulos, Meletios-Athanasios [4 ]
Fonseca, Rafael [5 ]
McFadden, Ian [6 ]
Yusuf, Akeem [6 ]
Khurana, Monica [6 ]
Obreja, Mihaela [6 ]
Spencer, Andrew [7 ]
机构：
[1] Univ Hosp Salamanca, Inst Canc Mol & Cellular Biol, Salamanca, Spain
[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[3] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia
[4] Natl & Kapodistrian Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, Athens, Greece
[5] Mayo Clin, Scottsdale, AZ USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
[7] Monash Univ, Alfred Health, Clayton, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-204
引用
收藏
页码：S150 / S151
页数：2
相关论文
共 50 条
  • [1] Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning
    Dimopoulos, Meletios Athanasios
    Landgren, Ola
    Siegel, David S.
    Grosicki, Sebastian
    Oriol, Albert
    Najdi, Rani
    Li, Chuang
    Mezzi, Khalid
    Shu, Natalie
    Quach, Hang
    BLOOD, 2023, 142
  • [2] Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies
    Quach, Hang
    Nooka, Ajay
    Samoylova, Olga
    Venner, Christopher
    Kim, Kihyun
    Facon, Thierry
    Spencer, Andrew
    Usmani, Saad
    Grosicki, Sebastian
    Suzuki, Kenshi
    Delimpasi, Sosana
    Weisel, Katja
    Obreja, Mihaela
    Zahlten-Kumeli, Anita
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S294 - S294
  • [3] Polyclonal immunoglobulin recovery in myeloma patients receiving maintenance after autologous hematopoietic stem cell transplantation with carfilzomib, lenalidomide and dexamethasone or lenalidomide
    Kubicki, Tadeusz
    Dytfeld, Dominik
    Wrobel, Tomasz
    Jamroziak, Krzysztof
    Robak, Pawel
    Czyz, Jaroslaw
    Tyczynska, Agata
    Druzd-Sitek, Agnieszka
    Giannopoulos, Krzysztof
    Nowicki, Adam
    Lojko-Dankowska, Anna
    Matuszak, Magdalena
    Gil, Lidia
    Pula, Bartosz
    Rybka, Justyna
    Usnarska-Zubkiewicz, Lidia
    Czabak, Olga
    Stefka, Andrew
    Jiang, Ken
    Derman, Benjamin
    Jakubowiak, Andrzej
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S259 - S260
  • [4] Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)
    Derman, Benjamin A.
    Cooperrider, Jennifer H.
    Rosenblatt, Jacalyn
    Avigan, David
    Rampurwala, Murtuza M.
    Major, Ajay
    Karrison, Theodore
    Jiang, Ken
    Kubicki, Tadeusz
    Jakubowiak, Andrzej J.
    BLOOD, 2023, 142
  • [5] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse
    Weisel, Katja
    Geils, George F.
    Karlin, Lionel
    Mollee, Peter
    Chung, Tae-Hoon
    Min, Chang-Ki
    Sunami, Kazutaka
    Goldrick, Amanda
    Fang, Belle
    Fowler, Jessica
    Mateos, Maria-Victoria
    BLOOD, 2020, 136
  • [6] Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma
    Baertsch, Marc-A.
    Fougereau, Mathilde
    Hielscher, Thomas
    Sauer, Sandra
    Breitkreutz, Iris
    Jordan, Karin
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Raab, Marc
    Hillengass, Jens
    Giesen, Nicola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S140 - S141
  • [7] Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Lonial, Sagar
    Benboubker, Lotfi
    Oriol Rocafiguera, Albert
    Arnulf, Bertrand
    San-Miguel, Jesus
    Pineiro, Luis
    Jakubowiak, Andrzej J.
    De Boer, Carla
    Wang, Jianping
    Schecter, Jordan Mark
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
    Baertsch, Marc-Andrea
    Fougereau, Mathilde
    Hielscher, Thomas
    Sauer, Sandra
    Breitkreutz, Iris
    Jordan, Karin
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Raab, Marc-Steffen
    Hillengass, Jens
    Giesen, Nicola
    CANCERS, 2021, 13 (18)
  • [9] Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients (Pts) with relapsed or refractory multiple myeloma.
    Siegel, David Samuel DiCapua
    Weisel, Katja
    Zahlten-Kumeli, Anita
    Medhekar, Rohan
    Sapra, Sandhya
    Ding, Bifeng
    Leleu, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
    Weisel, Katja
    Dimopoulos, Meletios A.
    Beksac, Meral
    Leleu, Xavier
    Richter, Joshua
    Heeg, Bart
    Patel, Sachin
    Majer, Istvan
    McFadden, Ian
    Mikhael, Joseph
    LEUKEMIA & LYMPHOMA, 2024, 65 (04) : 481 - 492
12345